FDA approved drug extends survival for patients with rare cancer

13 enero 2015

Sunitinib, an agent approved for use in several cancers, provides unprecedented antitumor activity in thymic carcinoma, a rare but aggressive tumor of the thymus gland, according to a phase II clinical trial.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/bJadfWR90MQ/150112191336.htm